{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:16:05Z","timestamp":1787494565279,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Higher doses of cytarabine appear to improve long-term outcome in acute myeloid leukemia (AML), in particular for younger patients. To this end, the optimal dosage of single-agent cytarabine in consolidation therapy remains elusive. Here, we assessed the impact of different dosages of cytarabine consolidation after 7\u2009+\u20093 induction on outcome in a large real-world data set from the German Study Alliance Leukemia-Acute Myeloid Leukemia (SAL-AML) registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients between 18 and 64\u00a0years of age, registered between April 2005 and September 2020, who attained complete remission after intensive induction and received at least one consolidation cycle with intermediate (IDAC) or high-dose cytarabine (HiDAC) were selected. To account for differences in patient and disease characteristics between both groups, the average treatment effect was estimated by propensity score weighting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six-hundred-forty-two patients received HiDAC consolidation with median dosage of  17.6 (IQR (interquartile range), 16.5\u201318.0) g\/m\n                      <jats:sup>2<\/jats:sup>\n                      for a median number of 3 cycles (IQR, 2\u20133), whereas 178 patients received IDAC consolidation with 5.9 (IQR, 5.7\u20138.6) g\/m\n                      <jats:sup>2<\/jats:sup>\n                      for a median of 2 cycles (IQR, 1\u20133). Both groups differed significantly in some important characteristics (age, sex, cytogenetic risk group, ECOG performance status, disease status, HCT-CI, number of induction cycles). After propensity score weighting for differences in patient and disease characteristics, relapse-free survival after 2\u00a0years was comparable between HiDAC-treated (55.3%) and IDAC-treated (55.6%) patients (HR\u2009=\u20090.935,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.69). Moreover, no significant differences in overall survival were observed after 2\u00a0years (84.7 vs. 80.6%, HR\u2009=\u20091.101,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.65). Notably, more patients treated with IDAC received allogeneic hematopoietic cell transplantation in first remission (37.6 vs. 19.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Censoring for allogeneic hematopoietic cell transplantation in first remission revealed no significant survival difference with regard to cytarabine dosage. Considering only of European LeukemiaNet (ELN) favorable-risk AML patients, there was no significant difference in outcome. Of note, significantly more patients treated with HiDAC suffered from\u2009\u2265\u20093 CTCAE infectious complications (56.7 [95%-CI 52.8\u201360.6%] vs. 44.1% [95%-CI 36.6\u201351.7%];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090,004). The rate of other\u2009\u2265\u20093 CTCAE non-hematological toxicities and secondary malignancies was comparable in both treatment groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This retrospective analysis suggests no significant benefit of high-dose cytarabine compared to intermediate dosages in consolidation for AML patients under 65\u00a0years of age, independent of ELN risk group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT03188874.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-022-04356-9","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T23:28:36Z","timestamp":1664321316000},"page":"4611-4621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intensified cytarabine dose during consolidation in adult AML patients under 65\u00a0years is not associated with survival benefit: real-world data from the German SAL-AML registry"],"prefix":"10.1007","volume":"149","clinical-trial-number":[{"clinical-trial-number":"nct03188874","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Maher","family":"Hanoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Ruhnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hanoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Henrik","family":"Mikesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Fransecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kullmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Seggewiss-Bernhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"G\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia D.","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Study Alliance Leukemia (SAL)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"4356_CR1","first-page":"4173","volume":"58","author":"CD Bloomfield","year":"1998","unstructured":"Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA et al (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173\u20134179","journal-title":"Cancer Res"},{"key":"4356_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447","journal-title":"Blood"},{"key":"4356_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3324\/haematol.2010.036921","volume":"96","author":"R Itzykson","year":"2011","unstructured":"Itzykson R, Gardin C, Pautas C, Thomas X, Turlure P, Raffoux E, Terre C, Fenaux P, Castaigne S, Dombret H et al (2011) Impact of post-remission therapy in patients aged 65\u201370 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica 96:837\u2013844","journal-title":"Haematologica"},{"key":"4356_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/bjh.17462","volume":"194","author":"BC Kolla","year":"2021","unstructured":"Kolla BC, Halim NAA, Cao Q, Sachs Z, Warlick E, Weisdorf D, Ho AYL, Chuan WG, Lao Z, He F (2021) High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature. Br J Haematol 194:140\u2013144","journal-title":"Br J Haematol"},{"key":"4356_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2012-07-444851","volume":"121","author":"B Lowenberg","year":"2013","unstructured":"Lowenberg B (2013) Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 121:26\u201328","journal-title":"Blood"},{"key":"4356_CR6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","volume":"364","author":"B Lowenberg","year":"2011","unstructured":"Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A et al (2011) Cytarabine dose for acute myeloid leukemia. N Engl J Med 364:1027\u20131036","journal-title":"N Engl J Med"},{"key":"4356_CR7","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood-2017-04-777722","volume":"130","author":"KN Magina","year":"2017","unstructured":"Magina KN, Pregartner G, Zebisch A, Wolfler A, Neumeister P, Greinix HT, Berghold A, Sill H (2017) Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood 130:946\u2013948","journal-title":"Blood"},{"key":"4356_CR8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJM199410063311402","volume":"331","author":"RJ Mayer","year":"1994","unstructured":"Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331:896\u2013903","journal-title":"N Engl J Med"},{"key":"4356_CR9","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2010-07-295279","volume":"117","author":"S Miyawaki","year":"2011","unstructured":"Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y et al (2011) A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood 117:2366\u20132372","journal-title":"Blood"},{"key":"4356_CR10","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1200\/JCO.2007.14.0418","volume":"26","author":"A Neubauer","year":"2008","unstructured":"Neubauer A, Maharry K, Mrozek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD (2008) Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 26:4603\u20134609","journal-title":"J Clin Oncol"},{"key":"4356_CR11","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1200\/JCO.2010.33.7303","volume":"29","author":"M Schaich","year":"2011","unstructured":"Schaich M, Rollig C, Soucek S, Kramer M, Thiede C, Mohr B, Oelschlaegel U, Schmitz N, Stuhlmann R, Wandt H et al (2011) Cytarabine dose of 36 g\/m(2) compared with 12 g\/m(2) within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol 29:2696\u20132702","journal-title":"J Clin Oncol"},{"key":"4356_CR12","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1200\/JCO.2012.46.4743","volume":"31","author":"M Schaich","year":"2013","unstructured":"Schaich M, Parmentier S, Kramer M, Illmer T, Stolzel F, Rollig C, Thiede C, Hanel M, Schafer-Eckart K, Aulitzky W et al (2013) High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol 31:2094\u20132102","journal-title":"J Clin Oncol"},{"key":"4356_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/16078454.2021.1912949","volume":"26","author":"K Tangchitpianvit","year":"2021","unstructured":"Tangchitpianvit K, Rattarittamrong E, Chai-Adisaksopha C, Piriyakhuntorn P, Rattanathammethee T, Hantrakool S, Tantiworawit A, Norasetthada L (2021) Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients. Hematology 26:355\u2013364","journal-title":"Hematology"},{"key":"4356_CR14","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1182\/blood-2011-04-349258","volume":"118","author":"X Thomas","year":"2011","unstructured":"Thomas X, Elhamri M, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terre C, Gardin C et al (2011) Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood 118:1754\u20131762","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04356-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04356-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04356-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T10:09:27Z","timestamp":1689415767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04356-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4356"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04356-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"14 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AH: research support by Novartis, BMS, Pfizer, Incyte.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol has been approved by the ethics committees of all participating centers and the study is registered (NCT03188874).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}